Replies to post #937 on Biotech Values

[mskatiescarletohara]

Dew--et al...

I think the real value will be returned to shareholders by advancing Squalamine into a well-controlled Phase II study, with a sub-study(s)attached for further labelling/dosing issues and perhaps a comparator study.

IMO, this latest placement deals directly with satisfying and perhaps stifling the FDA's cash concerns about conducting a Phase II study if a large patient population is being considered (75-100)? It's my understanding from some folks I know in the pharma industry that the FDA is real 'funny' about approving IND's if it's a financially struggling sponsor, this placement addresses that issue, and insures the patients enrolled will start and finish. Nothing is worse than starting a trial and not being able to complete it...ugh. Been there and done that with a few of these small-cappers. I am of the opinion an IND is close to being filed, getting money in the bank speeds this process, and IMO, will eventually enhance pharma negotiations after the trial is enrolled.

Will be interested in reading the SEC filing. Wonder who the investors are?

katie....

[dread50above]

Dew,
I'm an investing neophyte and really appreciate the excellent commentary of this board! Most educational.

Two questions:
1. Having read posts #692 and #937, you've calculated the underlying value of GENR to be approximately $10.75. What assumptions did you use in terms of a timeframe for realizing this value. Is there reason to expect a return in excess of a double (current price ~$5)?

2. Wondering if you've ever looked at DSCO, and if so, your thoughts.

Thanks. Back into the shadows......